Exhibit 99.1

March 6, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

This is in furtherance to the Company’s intimation dated November 19, 2020, and the continuing disclosures made as notes to the quarterly financial results and the audited financial statements filed with exchanges thereafter,  wherein it was informed that the Company commenced a detailed investigation into an anonymous complaint about allegation of improper payments to healthcare professionals in Ukraine and potentially in other countries, which could constitute violation of U.S. anti-corruption laws, including the U.S. Foreign Corrupt Practices Act. The matter was accordingly disclosed to the US Department of Justice (“DOJ”), United States Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India (“SEBI”). It was also informed that, at the directions of the committee of the Company's Board of Directors, the Company had engaged a U.S. law firm to conduct the investigation. The Company had further disclosed that such investigations could result in government or regulatory enforcement actions against the Company in the United States and/or foreign jurisdictions and can also lead to civil and criminal sanctions under applicable laws.

Subsequently, through its intimation dated February 24, 2026, the Company informed that it had received a letter from the SEC dated February 23, 2026, stating that, based on the information available to it, the SEC had concluded the above-referenced investigation and did not intend to recommend any enforcement action against the Company at that time.

In this regard, the Company now wishes to inform that it has received a letter dated March 5, 2026, from the U.S. Department of Justice, Criminal Division, Fraud Section (the “Department”), stating that, based on the information available to it, the Department has closed its inquiry under the Foreign Corrupt Practices Act, 15 U.S.C. § 78dd-l, et seq. The Department has not recommended any enforcement action against the Company.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR